Ozempic (semaglutide) is a once-weekly prescription glucagon-like peptide-1 (GLP‑1) receptor agonist used to improve blood sugar control in adults with type 2 diabetes, and to lower the risk of major cardiovascular events in adults with type 2 diabetes and established heart disease. It is not insulin, and it is not approved for people with type 1 diabetes or for diabetic ketoacidosis. CanadianInsulin® is a prescription referral service. Prescriptions are verified with your clinic, and orders are filled by licensed Canadian pharmacies.
Because GLP‑1 medicines also slow gastric emptying and help regulate appetite, some people lose weight while taking Ozempic. However, dosing and goals should be individualized, and semaglutide’s FDA-approved weight‑management indication is under a different brand (Wegovy), not Ozempic.
How Ozempic works
Semaglutide mimics the incretin hormone GLP‑1. When glucose levels rise after meals, it helps the pancreas release insulin and suppresses excess glucagon, lowering post‑meal and fasting glucose. It also slows stomach emptying, which blunts glucose spikes, and may reduce appetite signals in the brain. These effects can reduce A1C and aid cardiometabolic health when combined with nutrition, physical activity, and other therapies as needed.
Who might benefit—and who should avoid it
- Potential candidates: Adults with type 2 diabetes who need additional A1C reduction; adults with type 2 diabetes and established cardiovascular disease who may benefit from reduced risk of heart attack, stroke, or cardiovascular death.
- Not for: Type 1 diabetes; diabetic ketoacidosis; people with a personal/family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2); known hypersensitivity to semaglutide or any excipients.
- Use caution/close monitoring: History of pancreatitis, gallbladder disease, severe gastrointestinal disease (including gastroparesis), advanced diabetic retinopathy, kidney impairment (especially with dehydration risk), pregnancy or planning pregnancy, and while breastfeeding (limited human data).
Dosing at a glance
Ozempic is injected subcutaneously once weekly, on the same day each week, with or without food. To improve tolerability, dosing is titrated:
| Step | Weekly dose | Typical duration | Notes |
|---|---|---|---|
| Start | 0.25 mg | 4 weeks | For GI tolerability; not for glycemic control alone |
| Step 2 | 0.5 mg | At least 4 weeks | Evaluate A1C and side effects |
| Step 3 | 1 mg | As needed | Increase if additional control needed |
| Step 4 | 2 mg | As needed | For further A1C reduction if tolerated |
Missed dose: If less than 5 days have passed since a missed injection, take it as soon as possible and resume your usual schedule. If more than 5 days have passed, skip the missed dose and take the next dose on the regular day. You may change your weekly injection day if the last dose was at least 2 days (48 hours) earlier.
Sites: Inject into the abdomen, thigh, or upper arm. Rotate sites to reduce irritation.
Patients researching ozempic online often want to compare pen strengths and titration steps with their prescriber before starting or adjusting therapy.
Using the pen safely
- Storage: Keep unused pens refrigerated (2–8°C). Do not freeze. After first use, most pens can be kept refrigerated or at room temperature (below 30°C) and protected from light; discard after 56 days from first use (follow your local product leaflet).
- Needles: Always attach a new needle, perform a flow check per the pen’s instructions, and remove the needle after each injection to prevent leakage or contamination.
- Handling: Do not use pens that are frozen, expired, or visibly damaged; do not share pens or needles.
We collaborate with licensed, vetted pharmacy partners to supply authentic brand medications with a broad selection and value-focused pricing.
Common side effects and what to expect
Gastrointestinal symptoms are the most frequent and usually occur during dose escalation:
- Nausea, vomiting, diarrhea, constipation, abdominal discomfort, decreased appetite
Tips that may help: smaller meals; avoid heavy, high‑fat foods; sip fluids; pause dose escalations if symptoms are persistent—speak with your prescriber. Most symptoms lessen over time; persistent vomiting or inability to stay hydrated warrants medical attention.
Less common but important safety considerations:
- Pancreatitis: Severe abdominal pain that may radiate to the back, with or without vomiting—stop the drug and seek urgent care.
- Gallbladder issues: Gallstones or cholecystitis can occur; report right‑upper‑quadrant pain, fever, jaundice.
- Kidney injury: Usually linked to dehydration from GI losses; maintain hydration and monitor renal function if at risk.
- Diabetic retinopathy complications: Rapid A1C improvements can transiently worsen retinopathy; patients with existing retinopathy should have eye follow‑up.
- Hypoglycemia: Risk increases when used with insulin or sulfonylureas; your prescriber may lower those doses.
- Thyroid C‑cell tumor risk in rodents: Contraindicated with personal/family history of MTC or MEN2; report new neck mass, hoarseness, dysphagia, or dyspnea.
Drug interactions and timing considerations
- Delayed gastric emptying can affect the absorption of some oral drugs. While clinically significant interactions are uncommon, use caution with medicines requiring rapid GI absorption or narrow therapeutic windows. Monitor INR if on warfarin. For oral contraceptives, consistent use is generally effective, but vomiting/diarrhea may reduce reliability—follow backup guidance if needed.
- Combining with insulin or sulfonylureas increases hypoglycemia risk; discuss dose adjustments.
- Alcohol may worsen hypoglycemia risk and gastrointestinal side effects; moderation is advisable.
Alternatives if Ozempic isn’t suitable
- Other GLP‑1 receptor agonists: Dulaglutide (weekly), liraglutide (daily), exenatide (twice daily/weekly). Profiles differ in A1C reduction, weight effects, and side‑effect patterns.
- Tirzepatide: Dual GIP/GLP‑1 agonist with once‑weekly dosing; notable A1C and weight effects; similar GI considerations.
- SGLT2 inhibitors: Empagliflozin, canagliflozin, dapagliflozin—oral agents with benefits on heart failure and kidney outcomes in appropriate patients.
- Metformin, DPP‑4 inhibitors, thiazolidinediones, basal insulin, or combinations—selected based on A1C, comorbidities, cost, and tolerance.
For weight management in people without diabetes, semaglutide is available under the brand Wegovy, with a different dosing schedule and indication. Selection should be guided by medical history, cardiovascular and kidney status, and individual goals.
Practical points to discuss with your clinician
- Your A1C goal and whether a GLP‑1 agent aligns with your cardiovascular, kidney, and weight considerations.
- A titration plan and strategies to manage nausea or other GI effects.
- How Ozempic fits with existing therapies (insulin or sulfonylureas) to minimize hypoglycemia.
- Eye care follow‑up if you have diabetic retinopathy.
- Pregnancy planning: GLP‑1 agents are generally stopped before conception; discuss timelines.
Reading experiences and policies
If you want to see how others navigate GLP‑1 therapy and care coordination, browse independent customer testimonials with a critical eye—individual experiences vary widely and do not replace clinical guidance.
Those comparing access options sometimes look for manufacturer programs or pharmacy discounts; always verify legitimacy and storage requirements. You can check a provider’s availability and any current promotions alongside your prescriber’s recommendations and insurance coverage.
This article is informational and does not replace personalized medical advice. For service details and referral logistics, visit CanadianInsulin.
